Analyst Price Targets — RIGL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 11:05 am | — | Piper Sandler | $49.00 | $42.58 | TheFly | Rigel Pharmaceuticals price target raised to $49 from $40 at Piper Sandler |
| August 14, 2026 1:12 pm | Joseph Pantginis | H.C. Wainwright | $85.00 | $41.74 | TheFly | Rigel Pharmaceuticals price target raised to $85 from $57 at H.C. Wainwright |
| November 5, 2025 8:47 pm | — | Jefferies | $42.00 | $37.85 | TheFly | Rigel Pharmaceuticals upgraded to Buy from Hold at Jefferies |
| November 5, 2025 1:32 pm | — | Cantor Fitzgerald | $38.00 | $37.63 | TheFly | Rigel Pharmaceuticals price target raised to $38 from $32 at Cantor Fitzgerald |
| August 17, 2022 7:22 am | — | Piper Sandler | $2.00 | $1.56 | Benzinga | Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $2 |
| June 8, 2022 3:09 pm | Eun Yang | Jefferies | $1.00 | $0.71 | TheFly | Rigel Pharmaceuticals downgraded to Hold from Buy at Jefferies |
Latest News for RIGL
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September: Citi's 2026 Biopharma Back to School Conference in New York, NY Rigel will participate…
Canada Pension Plan Investment Board acquired a new position in Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 18,800 shares of the biotechnology company's stock, valued at approximately $735,000. Canada Pension Plan Investment
Connor Clark and Lunn Investment Management Ltd. bought a new stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 49,096 shares of the biotechnology company's stock, valued at approximately $1,921,000. Connor Clark
VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANUTM (vepdegestrant) is now available…
Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance. RIGL guides $285M–$295M 2026 revenues, excluding Veppanu upside. Upcoming R289 phase 1b data for LR-MDS and future readouts from Veppanu and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RIGL.
U.S. House Trading
No House trades found for RIGL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.